HDAC Inhibitors

 |  Home  |  Vorinostat  |  CI-994  |  MS-275  |  BML-210  |  M344  |  NVP-LAQ824  |  Panobinostat  |  Mocetinostat  |  PXD101  | 

NVP-LAQ824

LAQ824 is a very potent histone deacetylase inhibitor that is completing phase I clinical trial in solid and hematologic malignancies. LAQ824 has shown impressive antileukemic activity when administered in the low nanomolar range, making it a particularly attractive candidate for clinical development.

NVP-LAQ824

IUPAC Name:
((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
Molecular Weight: 379.46 g/mol
Molecular Formula: C22H25N3O3
SMILES: c3cccc1c3ncc1CCN(CCO)Cc(cc2)ccc2C=CC(=O)NO
Canonical SMILES: C1=CC=C2C(=C1)C(=CN2)CCN(CCO)CC3=CC=C(C=C3)C=CC(=O)NO
InChIKey Identifier: BWDQBBCUWLSASG-MDZDMXLPSA-N
CAS Number: 404951-53-7
Melting point: n/a °C
Solubility: : soluble in DMSO
2D Molfile: Get the molfile
Synonyms: NVP-LAQ824; LAQ824; Dacinostat

NVP-LAQ824 is approximately 50 000-fold more potent than the HDACI butyrate and its derivatives. It inhibits multiple myeloma cell growth and prolongs survival in a murine myeloma model, without toxicity to normal marrow or peripheral blood. A phase 1 clinical trial of NVP-LAQ824 in hematologic malignancies is now ongoing at the Dana-Farber Cancer Institute.

References:
1) Catley L et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
2) Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 2004; 259: 249266.
3) Atadja P, Gao L, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64:689695

HDACs


 |  CBHA  |  PCI-24781  |  ITF2357  |  Valproic Acid  |  Trichostatin A  |  Sodium Butyrate  |